MUC1 and cancer: TAA-targeting peptide vaccines have been widely developed from various cancer-related proteins such as VEGFR (Okuyama et al., 2013), HER2/neu (Knutson et al., 2001), CEA (Antonilli et al., 2016), MUC1 (Antonilli et al., 2016), survivin (Ciesielski et al., 2010), EGFR (Chen et al., 2018), and FR (folate receptor), and they have been applied in various cancers such as lung cancer (Mami-Chouaib et al., 2002), breast cancer (Peres Lde et al., 2015), liver cancer (Shen et al., 2017), melanoma (Ruiter et al., 1991), leukemia (Sugiyama, 2002), and ovarian cancer (Antonilli et al., 2016).